RETN and diabetes mellitus: Interestingly, myocardial-targeted restoration of Serca2a function in diabetic hearts markedly normalized resistin expression in these hearts to control levels (Fig. 1), raising the prospect that measures that underlie resistin repression through Serca2a activation may emerge as a potential objective in the treatment of diabetes-induced heart failure.